Exocrine pancreatic insufficiency (EPI) is a condition characterized by deficiency of the exocrine pancreatic enzymes. This results in the inability to digest food properly or maldigestion. These enzymes consist of lipases, proteases and amylases. These enzymes primarily consist of lipases for fat digestion, proteases for protein digestion, and amylases for starch digestion. EPI results from various diseases such as cystic fibrosis, chronic pancreatitis, pancreatic cancer, cytomegalovirus infection, and HIV/AIDS. The pancreatic enzyme products (PEPs) used for PERT are extracts of porcine pancreas that contain all 3 pancreatic enzymes such as amylase, protease, and lipase in varying proportions. A complete laboratory evaluation including pancreatic function testing is required to diagnose EPI and to determine the extent of the malabsorption. At present, six PEPs approved by the U.S. Food and Drug Administration (FDA) for the treatment of maldigestion in patients are creon, zenpep, pancreaze, ultresa, viokace and pertzye.
The global exocrine pancreatic insufficiency diagnostics market segmentation is based on diagnostic test types (blood tests, endoscopic ultra-sonography, magnetic resonance imaging, CT scanning). The global exocrine pancreatic insufficiency diagnostics market report provides market size (Revenue USD Million 2014 to 2021), market share, market trends and forecasts growth trends (CAGR%, 2017 to 2021).
The global exocrine pancreatic insufficiency diagnostics market report also provides the detailed market landscape, market drivers, restraints, opportunities), market attractiveness analysis and profiles of major competitors in the global market including company overview, financial snapshot, key products, technologies and services offered, and recent developments. The global exocrine pancreatic insufficiency diagnostics market research report is divided by geography (regional and country based) into North America (U.S., Canada), Latin America (Brazil, Mexico, Rest of LA), Europe (U.K., Germany, France, Italy, Spain, Rest of EU), Asia Pacific (Japan, China, India, Rest of APAC), and Rest of the World.
Major players operating in the global exocrine pancreatic insufficiency diagnostics market and included in this report are AbbVie, Inc., Nordmark Arzneimittel GmbH & Co. KG, Allergan Plc., Digestive Care, Inc., Janssen Pharmaceuticals, Inc., and others.